Brook­lyn Health rais­es $6.5M to stan­dard­ize men­tal health as­sess­ment

3 days ago
Financing
Health Tech

Black­stone's GRIN inks epilep­sy li­cens­ing deal with An­geli­ni, clos­es $140M Se­ries D

3 days ago
Deals
Pharma

Up­dat­ed: Pa­tient dies in Rock­et gene ther­a­py tri­al, which is put on clin­i­cal hold by FDA

3 days ago
Cell/Gene Tx
FDA+

Prothena’s amy­loi­do­sis drug flops again, spend­ing and staff cuts are on the way

3 days ago
People
R&D

In­vestors pump $130M in­to pro­tein de­grad­er start­up Gly­co­Era

3 days ago
Financing
Startups

Syn­deio de­buts with $90M+ to bring to­geth­er synapse re­pair drugs

3 days ago
Financing

Ex­clu­sive: Toron­to biotech Pro­tein­Qure nears the clin­ic with pep­tide plat­form as it rais­es $11M Se­ries A

3 days ago
Financing

TCG's R&D ven­ture team makes a T cell en­gager deal with Shang­hai biotech

3 days ago
Startups
Deals

An­a­lyz­ing the End­points 100; ‘Most fa­vored na­tion’ tar­gets re­vealed; Biotech slump makes leas­es a li­a­bil­i­ty; and ...

6 days ago
Weekly

About 5% of CBER and CDER left af­ter FDA staff cuts, analy­sis finds

Last week
People
FDA+

Trump asks 'very tough hom­bre' Dr. Oz to lead MFN talks

Last week
Pharma

US warns drug­mak­ers against mis­rep­re­sent­ing cost of im­port­ed prod­ucts

Last week
Pharma
Manufacturing

CHMP clears path for GSK’s Blenrep re­launch, rec­om­mends four oth­er drugs 

Last week
Pharma
FDA+

Ku­ra spells out piv­otal AML tri­al win as it gears up to com­pete with Syn­dax

Last week
R&D

GLP-1s may cut can­cer risk; Gyre’s stock falls af­ter hep B da­ta and of­fer­ing

Last week
News Briefing

Fed­er­al judge ex­tends or­der block­ing RFK Jr. from re­or­ga­niz­ing HHS

Last week
FDA+
Law

Gilead notch­es an­oth­er Phase 3 win for Trodelvy in triple-neg­a­tive breast can­cer

Last week
R&D
Pharma

Ge­of­frey Porges ex­its Schrödinger with CFO swap; A new board seat for As­traZeneca's Pas­cal So­ri­ot

Last week
Peer Review

Volas­tra un­veils first hu­man da­ta of its sol­id tu­mor drug tar­get

Last week
R&D

Merus’ Phase 2 over­all sur­vival da­ta reach ‘home run’ sce­nario — an­a­lyst

Last week
R&D

GSK’s Nu­cala wins COPD ap­proval, stok­ing ri­val­ry with Dupix­ent 

Last week
Pharma
FDA+

Roche con­firms over­all sur­vival ben­e­fit for PI3K in­hibitor in breast can­cer

Last week
R&D
Pharma

Jazz out­lines full sur­vival da­ta for lung can­cer drug Zepzel­ca

Last week
R&D
Pharma

Up­dat­ed: FDA ex­pects 'time­ly avail­abil­i­ty' of Covid shots as ad­vi­sors up­date for­mu­la rec­om­men­da­tion

Last week
FDA+
Coronavirus
First page Previous page 123456 Next page Last page
A service from the Financial Times